Global distribution of heterogeneous vancomycin-intermediate Staphylococcus aureus strains (1997–2021): a systematic review and meta-analysis

Real-World Use and Treatment Outcomes of Ceftaroline Fosamil in Patients with Complicated Skin and Soft Tissue Infection: A Multinational Retrospective Study

“… 6 , 8 Moreover, the global prevalence of vancomycin-resistant S. aureus , vancomycin-intermediate S. aureus (VISA), and heterogeneous VISA (hVISA) is generally reported to be increasing, including in countries in Europe, Asia, and America. 9 , 10 hVISA numbers in Latin America are reported to be relatively low, but rising, although data from Latin American countries are recognized to be grossly underrepresented. 11 , 12 Increasing prevalence of resistant strains will potentially reduce the effectiveness of vancomycin treatment in the coming years.…”

“… 11 , 12 Increasing prevalence of resistant strains will potentially reduce the effectiveness of vancomycin treatment in the coming years. 9 Therefore, there is a need for alternative options for the treatment of infections suspected to be caused by MRSA.…”